Surefire Medical Launches New Precision Device
with Increased Length and 1200 PSI Rating

New device provides for additional access in patient procedures, improved imagery

April 3, 2016—Vancouver, Canada—Surefire Medical, Inc. today announced the launch of a new Precision Infusion System at the Society for Interventional Radiology (SIR) meeting in Vancouver, Canada. The new Precision system has an increased length of 150 centimeters and pressure rating of 1200 pounds per square inch (PSI), which will provide physicians additional access during patient procedures and enable higher injection pressure for improved angiographic imaging.

With the increased length made available by this product extension, physicians can now also use Surefire technology in radial artery access procedures, which can help increase patient comfort, speed recovery as well as lower the risk of potential post-procedure complications.

“Surefire Medical is pioneering site-specific drug delivery products that overcome the limitations of traditional tools and delivery methods,” said James E. Chomas, President and CEO of Surefire Medical. “This 150 cm Precision system does just that – arming physicians who prefer radial access to target tumors and deliver therapies with superior accuracy, control and protection.”

The increased pressure rating of 1200 PSI on the new Precision product extension allows physicians to significantly increase the flow rate during infusion and is designed to enhance angiographic visualization. The Surefire Precision Infusion System with increased pressure rating continues to be available in the 120 centimeter length.


About Surefire Medical

Surefire Medical is inventing the future for cancer care with advanced treatment technology. We are pioneers, developing liver cancer infusion systems that overcome the limitations of traditional tools and delivery methods. Clinical discoveries combined with new, precise technology enable physicians to target tumors with superior accuracy, control and protection. Our Colorado-based team of physicians, engineers and researchers are united in a mission to progress cancer care and offer new hope to patients. Learn more:


Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.